From: Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes
RTOG Grade
I
II
III
IV
Urinary
25% (10/41)
7% (3/41)
2.5% (1/41)
0%
Rectal
13%
(6/41)
2.5%
(1/41)